{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:26:24Z","timestamp":1785410784828,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.esmoop.2024.103606","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T18:56:35Z","timestamp":1718823395000},"page":"103606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-6074","authenticated-orcid":false,"given":"K.","family":"Takemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lemelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7798-0231","authenticated-orcid":false,"given":"E.","family":"Ferrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-1405","authenticated-orcid":false,"given":"J.C.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-9312","authenticated-orcid":false,"given":"E.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Saliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.S.","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5994-4547","authenticated-orcid":false,"given":"E.","family":"Jude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-863X","authenticated-orcid":false,"given":"F.","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7427-9102","authenticated-orcid":false,"given":"B.","family":"Beuselinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Szabados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-6415","authenticated-orcid":false,"given":"G.","family":"Gebrael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"N.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.Y.C.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2024.103606_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamaoncol.2021.4337","article-title":"Treatment selection in first-line metastatic renal cell carcinoma-the contemporary treatment paradigm in the age of combination therapy: a review","volume":"8","author":"Navani","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103606_bib2","series-title":"Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma","first-page":"233","article-title":"Prognostic factors in advanced renal cell carcinoma","author":"Takemura","year":"2023"},{"issue":"34","key":"10.1016\/j.esmoop.2024.103606_bib3","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103606_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","article-title":"Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma","volume":"84","author":"Ernst","year":"2023","journal-title":"Eur Urol"},{"issue":"1-2","key":"10.1016\/j.esmoop.2024.103606_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103606_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"issue":"7652","key":"10.1016\/j.esmoop.2024.103606_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103606_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jjco\/hyab157","article-title":"Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"52","author":"Ueda","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103606_bib9","first-page":"1166","article-title":"Prognostic significance of the\u00a0controlling nutritional status (CONUT) score in patients with\u00a0advanced renal cell carcinoma treated with nivolumab after failure of prior tyrosine kinase inhibitors","volume":"204","author":"Takemura","year":"2020","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103606_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103606_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?","volume":"7","author":"Menetrier-Caux","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103606_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103606_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jgo.2014.01.001","article-title":"Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer","volume":"5","author":"De Giorgi","year":"2014","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103606_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clgc.2020.06.003","article-title":"Addition of primary metastatic site on bone, brain, and liver to IMDC criteria in patients with metastatic renal cell carcinoma: a validation study","volume":"19","author":"Massari","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmoop.2024.103606_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2024.103606_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103606_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.bjc.6600437","article-title":"Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival","volume":"87","author":"Donskov","year":"2002","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103606_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103606_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","article-title":"Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma","volume":"6","author":"Lalani","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103606_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100634","article-title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","volume":"7","author":"Rebuzzi","year":"2022","journal-title":"ESMO Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T04:43:50Z","timestamp":1722401030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924013759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2059702924013759"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103606","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103606"}}